Harbour BioMed inks $350 million deal for rights to A167
Member News
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Related or similar articles
May 17, 2024
Streamlining Procurement: Labshares Partners with Labviva for Enhanced Access and Efficiency
In the fast-paced world of biotech innovation, easy access to crucial resources is vital for research success. That's why Labshares is excited to share news of our partnership with Labviva, a top procurement platform reshaping how scientists obtain l
Labshares News
April 14, 2019
Global 3D Printed Drugs Market Insights 2019-2024 : Extend Biosciences, Bioduro, Affinity Therapeutics
One of the dominating players in the 3D Printed Drugs market is Extend Biosciences
Member News
August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News